Skip to main content

Our roundup of Canadian small-caps of between $100-million and $2.5-billion in market capitalization making news and on the move today.

Equitable Group Inc. (EQB-T) announced that it has selected Barclays Bank PLC and TD Securities to help its Equitable Bank subsidiary with developing a covered bond funding program. “Management’s goal is to launch the program as early as 2020, subject to regulatory approval of its program and market conditions. Assuming success with this timetable, Equitable would likely become the first mid-sized Canadian bank to launch a covered bond program,” the company stated.

**

Story continues below advertisement

Medicure Inc. (MPH-X) announced that its Medicure International Inc. subsidiary has settled its ongoing patent infringement action against Gland Pharma Ltd. in the U.S. District Court for the District of New Jersey, which alleged infringement of one of Medicure’s U.S. patents.

"As part of the settlement, Gland has acknowledged that the '660 patent is valid, enforceable and infringed," the company stated. "The settlement results in the company entering into a license agreement with Gland with an anticipated launch date for Gland's generic product of March 1, 2023. The remaining terms of the settlement are confidential."

**

Cresco Labs Inc. (CL-C) reported second-quarter revenue of $29.9-million, up 253 per cent year-over-year. and ahead of expectations of $27.9-million. Its net loss of $3.9-million, compared to net income of $1.6-million in the prior-year period

**

Kirkland Lake Gold Ltd. (KL-T) increased its stake in Bonterra Resources Inc. (BTR-X) to 11.3 per cent from 10.2 per cent on a non-diluted basis. The company said it bought 2 million units in a private placement financing at a price of $2.50 per unit for a total cash payment of $5-million. Each Unit is comprised of one common share and one-half of one share purchase warrant. Each full warrant entitles the company to acquire one share at a price of $3.10 until August 20, 2021.

**

Story continues below advertisement

Well Health Technologies Corp. (WELL-X) reported that its revenue increased 258 per cent to $7.4-million in the three-month period ended June 30, compared $2.1-million in the three months ended July 31, 2018 and ahead of expectations of $6.96-million. Its net loss from continuing operations was $1.7-million or 2 cents per share, which was in line with expectations and compared to a loss of $633,270 or a penny per share in the second quarter of last year.

**

TerrAscend Corp. (TER-C) reported second-quarter revenue of $17.6-million up from $9,000 a year ago. Its net loss was $21.5-million or 37 cents per share compared to $5.2-million or 5 cents a year ago. The company also raised its guidance and says revenues are now expected to exceed $141-million1 in 2019, up from $135-million as previously announced on April 15.

**

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter